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Since etretinate, an aromatic retinoid useful in the 
treatment of psoriasis and other skin disorders is lipid-
soluble, it may be poorly absorbed in the absence of a 
fat load. We therefore studied serum concentrations of 
etretinate and its major metabolite (Ro 10-1670) after 
the controlled administration of etretinate. After an 
overnight fast, 6 Darier's disease and 4 psoriatic pa-
tients received a 1 mgjkg morning dose of etretinate 
with water or 1 pint of whole milk (fat load). There was 
a 260% increase (p < 0.0005) in the mean of each 
patient's increase in the baseline-corrected peak serum 
concentration of etretinate after administration with 
milk (115 ± 15 1-Lg/dl) compared to after administration 
with water (32 ± 4 1-!g/dl). Over a 24-h period there was 
an overall 296 ± 26% (p < 0.0005) increase in serum 
etretinate after administration with milk compared to 
water in 5 patients with Darier's disease. In contrast to 
the serum etretinate, there was a 17% mean decrease (p 
< 0.025) in the corrected peak serum concentration of 
Ro 10-1670 in all 10 patients after administration of 
etretinate with milk compared to water. The net r esult 
of these alterations is that the mean corrected serum 
concentration of etretinate is higher than Ro 10-1670 
at all time points measured after milk administration. 
In contrast, after administration of etretinate with 
water the major retinoid in the serum is Ro 10-1670. 
Establishing the clinical significance of these alterations 
may require controlled clinical trials. 
Etretinate (Ro 10-9359), an aromatic retinoid , is an experi -
menta l t he rapy for psoriasis a nd disorders of keratinization . 
This ethy l ester of t he t rimethy lmethoxyphe ny l (TMMP) de-
riva t ive of a ll -tra.n.s-retinoic acid (Fig 1) differs from the natu-
ra lly occurrin g all -trans-retinoic acid by the presence of a n 
aromatic ring and an ethyl ester e nd group. In t he gut, liver, 
a nd blood, the este r group is enzym atica lly hydrolyzed yielding 
t he TMMP ac id Ro 10-1670 (Fig 1) (1] . F ollowing o ra l admin-
istratio n of etretina te to psoriatic patien ts, both unchanged 
drug a nd t he metaboli te, Ro 10-1670, have been detected in the 
plasm a (2]. But t he metabolite concentrations after an i.v. 
bolus of etreti nate a re re lative ly low, suggestin g presyste mi c 
hydrolys is of etretinate [3]. 
The absorption of vitamin A itself a nd other lipid-soluble 
dru gs, suc h as gri seofulvin , an o ral antifungal agent, a re known 
Manuscript received Octobe r 13, 1983; accepted for publication 
Februa ry 8, 1984. 
• This paper was presented in part at the National Meeting of The 
Society for Investigative Dermatology, Washingto n, D.C., May 6- 8, 
1982. 
Reprint requests to: J ohn J . DiGiovanna, M.D., Bldg 10, Rm 12N238, 
Derma tology Branch, National Institu tes of Health, Bethesda, Mary-
land 20205. 
Abbreviat ions: 
CPSC: corrected pea k se rum concent ration(s) 
H PLC: high-pressure liquid chromatography 
M: milk 
TMMP: tr imethylmethoxyphenyl 
W: water 
to be inc reased by feeding with fa ts (4]. Since etretinate, like 
vitamin A a nd griseofu lvin, is fat-so luble and only poorly 
soluble in wate r, it may require a fat load to be well absorbed. 
In t reating a variety of disorders with etretinate our impres-
s ion has been that the therapeutic response and side effects 
may vary among pat ients and within the same patient over 
time. If etretinate absorption varied greatly with mode of 
administration t hese differences in absorption might exp la in 
som e of t he variab le clinical responses . 
To in vestigate t he effect of fat intake on blood levels of 
etretinate we m easured t he se rum concen tration of etretinate 
and its major metabolite (Ro 10-1670) after a s ingle oral dose 
given with or without a fat load. 
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MATERIALS AND METHODS 
Patients 
Six patients wi th Darier's disease (keratosis folli cula ris) and 4 with 
psorias is vulgaris receiving 6- month courses of et retinate separated by 
treatment- free intervals were included in this study. One patient with 
Darier' s disease had no prior treatment with etret inate; t he other 9 
patients had been under treatment for 2.5- 4.5 years prior to inclusion 
in t his study. 
Procedure 
Patients receiving a course of t herapy at t he time the study was 
performed were not given etretinate for at least 24 h prior to t he study. 
After a 12-h fast, each patient was given a 1 mg/kg morning oral dose 
of etret inate with either 1 pint of whole milk (approximately 17 g fa t) 
or water. Whole milk was chosen as the fat load because it was easily 
ava ilable, well tolerated by most of our patients, contained a repro-
ducible quantity of fat, and has been shown to fac ili tate t he absorp tion 
of griseofulvin, another lipophilic drug ]4]. After administration of 
etretinate, the patients remained fasting 4 h before returning to an ad 
li b diet. A se ries of light-protected serum samples were drawn imme-
di ate ly before administration of t he drug (zero time) and at various 
t ime periods thereafter. 
Retinoid Analys is 
Under dim ye llow light (Westinghouse 9Y-T192- l bulb) the speci-
mens were extracted and analyzed by high-p ressure liquid chromatog-
raphy (HPLC) for etretinate and Ro 10-1670 as previously described 
[5]. One milliliter of serum was extracted with 400 1'1 of a 1:1 bu -
tano l:acetonitrile solution to which 300 J.<l of a dipotassium monohy-
drogen phosphate solu tion (1.2 kg/ li ter) was added. Following cent ri f-
ugation, 80 1'1 of the supernatant was injected onto t he column. The 
mobile phase was 0.5:20.0:79.5 acetic ac id:water:acetonitr ile employed 
at a fl ow rate of 3.0 ml / min . Detection of the eluted compounds was 
accom plished wi th a var iable- wavelen gth detector set at 360 nm. Re-
tinyl acetate was used as the in ternal sta ndard. 
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Correction for Baseline Values 
In patients recen tly t reated with etretinate, dai ly changes in serum 
concentrations are superimposed on a ba eli ne (steady state or equilib-
rium) concentration. The baseline concentrations of etretinate and Ro 
10-1670 are dependent on the prior dose and duration of etretinate 
administration. In order to compare patients with different histories of 
etr etinate administration , we corrected for this baseline in each run by 
subtract ion of the ze ro time value. 
Co rrected Peak Seru.m Concentrations 
Peak serum concentrations occurred most often at the 4-h time but 
were also observed at 2 or 6 h. The corrected peak serum concentration 
(CPSC) was the highest serum retinoid co ncentration measured within 
the series (regardless of the time at which it occurred) minus the 
baseline (zero t ime) value. 
ta.tistical Analysis 
Comparison Between Mill~ and Water Administration: The difference 
between CPSC of etretinate obtained after milk (M) and water (W) 
administration was statistically analyzed by comparing the mean per-
ce n t difference of the CPSC in each patient 
(M- W ) -----w- X 100 
to zero using a one-tailed t-test. 
The difference between the mean corrected serum etretinate curves 
was determined by ca lculating the percent increase for each individual 
patient at each time point 
( M- W ) -----w- X 100 , 
a nd then ca lculating the mean percent increase for all patients. At each 
ti m e point, the increase was compared to zero by a one-tailed t-test. 
Comparison Between Ret inoids Within Each Mode of Administration: 
The percent increase in the relative serum ret inoid concentration was 
ca lc ulated for each patient. At each time point after milk ad minstration, 
s ince the serum co ncentration of etretinate was higher than Ro 10-
1670, the percent increase of etretinate over Ro 10-1670 was calculated 
as: 
etretinate - Ro 10-1670 
..:..:;:_..:..:;:_---'------- X 100 
Ro 10-1670 
After water adm inistration the Ro 10-1670 concentration in the 
serum was hi gher than etretinate, therefore, the percent increase of Ro 
10-1670 over etretinat.e was calculated as: 
Ro 10-1670 - etretinate OO 
. X 1 . 
etretmate 
In both cases the mean change at each time poin t was compared to 
ze r o using a two-tailed t-test. 
RESULTS 
Baseline Concentrations 
The typ ica l curve after both mi lk a nd water administration 
depicts the serum concentrations of etretinate and Ro 10-1670 
rising to a peak between 2-6 h after dos ing, then rapidly 
d ec lining ove r t he rema inder of t he first day to a level s imi la r 
to t he initial zero time concentration. Wit hin each run the zero 
t im e va lue and 24- h values were simi lar, suggesting that both 
before each seri es was begun a nd at the 24-h time an equilib-
ri urn had been reached between t he blood and tissue stores. 
After t he 24- h t ime t he se rum concent rations s lowly decline. 
In our patient group t he ze ro ti me serum retinoid concent ra-
tions were subtracted from each value within each run to 
facilitate comparison of patien ts with different histo ries of 
etr etinate administration. There was no significant diffe rence 
in mean zero time serum etre tinate concentration between the 
milk (10.2 ± 2.8 J.Lg/dl) and water series (13.7 ± 2.5 J.L g/dl) . 
There was a lso no significant difference in the mean zero time 
serum Ro 10-1670 concentrations between t he mi lk (2.0 ± 0.8 
J.Lg/dl) a nd wate r series (3.9 ± 0.9 J.Lg/ dl). 
Corrected Pea.h Serum Etretinate Concentrations 
After baseline correction t he highest or peak serum concen-
t ration of etretinate measured (rega rdless of whether it oc-
cur-red at 2, 4, or 6 h ) was plotted for milk and water adminis-
t ration for each patient. As shown in Fig 2, the CPSC of 
etretinate a fte r m ilk administration was higher than t hat after 
water administration in every patie nt tested. The mean CPSC 
of etretinate was 259% greater after administration wit h milk 
(115 ± 15 J.Lg/ dl) than after administrat ion with water (32 ± 4 
J.Lg/d l). 
One patient wi t h Da ri er 's di sease had no prior oral synt hetic 
retinoid treatment before hav ing the milk study performed. 
Three days late r, with no in te rvening re t inoid, t he water study 
was performed. In t hi s patien t, whose baseline serum concen -
t rations were ze ro for both studies, t he peak serum concentra-
tion of etretinate during t he milk study (40 J.Lg/ dl) was higher 
t han t hat during the water study (10 11g/ dl). This suggests that 
the higher CPSC observed afte r milk is not due sole ly to a fat. 
load-induced re lease of drug from a ga llbladder sto re. This 
patient, with no prior etretinate t reatment would have no 
gallb ladder store, yet had higher erum levels of etretinate a fter 
administ ration with milk . 
After water administration, the mean CPSC of etretinate for 
t he psoriasis subgroup (45 ± 2 J.Lg/dl) was higher (two-tai led p 
< 0.01) t ha n for the Darier's disease subgroup (24 ± 4 J.Lg/ dl). 
After milk administration, t he mean CPSC of etretinate for t he 
pso rias is subgroup (151 ± 21 J.Lg/ dl) was not significan tly higher 
than for the Darier's di sease subgroup (91 ± 40 J.Lg/dl ). 
The percent increase after milk 
( M- W ) W X 100 
in the CPSC of etretinate was calculated for each patient.. 
Darier's di sease a nd psorias is patients' va lues were analyzed 
separately. The mea n increase in t he CPSC of etretinate for 
t he 6 patients with Darier's disease was 275 ± 31 % (one-tai led 
P < 0.0005). The subset of 4 patients with psoriasis had a mean 
increase in t he CPSC of etretinate of 239 ±50% (one-ta il ed p 
< 0.01) after milk administrat ion . There was no s igni ficant 
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FIG 2. Co rrected peak se rum etretinat.e concentration after adm in-
istration with milk or water. All patients had higher serum etretinate 
concentrat ions after administration with milk compared to wate r. Bar 
represents mean ± SEM. = psoriasis, ---- - = Darier's 
disease. 
